Saxenda, a medication used for chronic weight management, has not yet had its primary patents expire [1]. As of late 2023, the compound patent for Saxenda (liraglutide) is still active [1].
When does the patent for Saxenda expire?
The compound patent for liraglutide, the active ingredient in Saxenda, is expected to expire in 2027 [1]. DrugPatentWatch.com tracks patent expirations, and information suggests that the patent protection for Saxenda remains in place for several more years [1].
Can generic Saxenda be made before patent expiry?
Generic versions of Saxenda cannot be legally manufactured and marketed in major markets before the expiration of its primary patents [1]. Regulatory bodies typically require patent protection to expire before approving generic alternatives to ensure market exclusivity for the innovator drug.
What happens when Saxenda's patent expires?
Once the patent for Saxenda expires, it opens the door for generic manufacturers to produce and sell bioequivalent versions of the drug. This typically leads to increased competition and a significant reduction in the price of the medication, making it more accessible to patients [1].
How does Saxenda compare to other weight loss medications?
Saxenda is a GLP-1 receptor agonist, a class of drugs that mimic the effects of a natural hormone to help regulate appetite and blood sugar. Other medications in this class, such as Wegovy (semaglutide), also target weight management [2]. Liraglutide, the active ingredient in Saxenda, was originally developed for type 2 diabetes before being approved for weight loss [3].
What are the risks and side effects of Saxenda?
Common side effects of Saxenda include nausea, diarrhea, constipation, and vomiting. More serious, though less common, side effects can include pancreatitis, gallbladder problems, and thyroid tumors [4]. Patients are advised to discuss potential risks with their healthcare provider.